Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | IKBKB | O14920 | 14/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | CHUK | O15111 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519764 | 0.88 | IKBKB (0.97) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL3519939 | 0.86 | IKBKB (1.00) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL3647596 | 0.84 | DKK1 (0.72) | DKK1GSK3BIKBKBKDM4EMEN1 | |
| SCHEMBL3518391 | 0.83 | IKBKB (0.72) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL3521072 | 0.82 | IKBKB (0.74) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL3520123 | 0.82 | IKBKB (0.74) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL3518914 | 0.82 | IKBKB (0.74) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL3518049 | 0.81 | IKBKB (0.79) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL3520622 | 0.81 | IKBKB (0.79) | DKK1GSK3BIKBKBMAPK8MAPK10 | |
| SCHEMBL7470673 | 0.81 | IKBKB (0.81) | DKK1GSK3BIKBKBMAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | claimed |
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | DKK1 11/4885GSK3B 263/4885IKBKB 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.